Balance Sheet
Liabilities and Shareholders Equity
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Cash & Equivalents (2016 - 2024)

KalVista Pharmaceuticals' Cash & Equivalents history spans 10 years, with the latest figure at $182.3 million for Q4 2024.

  • For Q4 2024, Cash & Equivalents changed N/A year-over-year to $182.3 million; the TTM value through Dec 2024 reached $182.3 million, changed N/A, while the annual FY2024 figure was $31.8 million, N/A changed from the prior year.
  • Cash & Equivalents for Q4 2024 was $182.3 million at KalVista Pharmaceuticals, up from $41.6 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $182.3 million in Q4 2024 and bottomed at $15.8 million in Q2 2020.
  • The 4-year median for Cash & Equivalents is $27.4 million (2024), against an average of $42.0 million.
  • The largest annual shift saw Cash & Equivalents plummeted 66.96% in 2020 before it fell 4.77% in 2021.
  • A 4-year view of Cash & Equivalents shows it stood at $16.2 million in 2020, then increased by 9.6% to $17.7 million in 2021, then surged by 225.3% to $57.7 million in 2023, then soared by 216.18% to $182.3 million in 2024.
  • Per Business Quant, the three most recent readings for KALV's Cash & Equivalents are $182.3 million (Q4 2024), $41.6 million (Q4 2024), and $31.8 million (Q3 2024).